ClinVar Miner

Submissions for variant NM_001365276.2(TNXB):c.9668del (p.Gly3223fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV004018293 SCV004847415 likely pathogenic Ehlers-Danlos syndrome due to tenascin-X deficiency 2024-01-07 criteria provided, single submitter clinical testing The p.Gly3223AlafsX51 variant in TNXB has not been previously reported in individuals with Ehlers-Danlos syndrome (EDS) but has been identified in 0.001% (1/68014) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 3223 and leads to a premature termination codon 51 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Biallelic loss of function of the TNXB gene is an established disease mechanism in autosomal recessive EDS. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal recessive EDS. ACMG/AMP Criteria applied: PVS1, PM2_Supporting.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.